Literature DB >> 8543792

Structure and expression of murine CD30 and its role in cytokine production.

M A Bowen1, R K Lee, G Miragliotta, S Y Nam, E R Podack.   

Abstract

Murine CD30 cDNA predicts a protein of 498 amino acids with homology to the TNF receptor family of proteins characterized by repeated cysteine-rich motifs in the extracellular domain. Murine CD30, although homologous to human CD30, has a 90 amino acid gap in an extracellular region that appears to be duplicated in human CD30. Murine CD30 cDNA was shown to be functional through the production of a soluble murine Ig fusion protein (CD30-Ig) that was active in binding to cells that expressed CD30 ligand. CD30-Ig also served as an immunogen for the production of hamster anti-mouse CD30 mAbs, which recognized both CD30 expressed by murine lymphocytes and CD30 expressed by cells transfected with murine CD30 cDNA. CD30 mRNA is highly expressed in the thymus and in activated spleen cells, but not in other tissues tested. In anti-CD3-activated spleen cells, CD30 ligand is expressed primarily by CD4+ T cells, with peak expression at days 1 and 2, whereas CD30 is expressed primarily by CD8+ T cells, with peak expression on days 4 and 5. Stimulation of CD30 by plate-bound anti-CD30 directly signaled for IL-5 but not IFN-gamma production by CD30+ CTL lines. These studies demonstrate that CD30 directs cytokine secretion and suggest that CD30 signaling may be pivotal in the pattern of cytokine production by T cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8543792

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene.

Authors:  E J Croager; A M Gout; L J Abraham
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

2.  CD4+CD25+ regulatory T cells suppress allograft rejection mediated by memory CD8+ T cells via a CD30-dependent mechanism.

Authors:  Zhenhua Dai; Qi Li; Yinong Wang; Ge Gao; Lonnette S Diggs; George Tellides; Fadi G Lakkis
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

3.  Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease.

Authors:  Robert Zeiser; Vu H Nguyen; Jing-Zhou Hou; Andreas Beilhack; Elizabeth Zambricki; Martin Buess; Christopher H Contag; Robert S Negrin
Journal:  Blood       Date:  2006-10-26       Impact factor: 22.113

4.  Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice.

Authors:  Joel N H Stern; Derin B Keskin; Hong Zhang; Huijuan Lv; Zenichiro Kato; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

5.  CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity.

Authors:  S Y Lee; S Y Lee; G Kandala; M L Liou; H C Liou; Y Choi
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

6.  Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2.

Authors:  C S Duckett; R W Gedrich; M C Gilfillan; C B Thompson
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

Review 7.  CD30+ Lymphoproliferative Disorders of the Skin.

Authors:  Maxwell B Sauder; John T O'Malley; Nicole R LeBoeuf
Journal:  Hematol Oncol Clin North Am       Date:  2017-04       Impact factor: 3.722

Review 8.  TNF superfamily: costimulation and clinical applications.

Authors:  Dass S Vinay; Byoung S Kwon
Journal:  Cell Biol Int       Date:  2009-02-20       Impact factor: 3.612

Review 9.  Role of CD30 targeting in malignant lymphoma.

Authors:  Anita Kumar; Anas Younes
Journal:  Curr Treat Options Oncol       Date:  2014-06

Review 10.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.